

Luminex acquires MilliporeSigma's flow cytometry portfolio

Jan. 14, 2019—[Luminex](#) has completed its acquisition of MilliporeSigma's flow cytometry portfolio for \$75 million. The flow cytometry portfolio includes the Amnis family of imaging flow cytometry products for cell-based analysis and the Guava portfolio of microcapillary flow cytometry systems.

"The Amnis and Guava products complement our wide range of existing flow-based offerings, further differentiating our portfolio and ensuring we are well positioned to support customers today and into the future," Homi Shamir, president and CEO of Luminex, said in a press release. "With this acquisition, we now have expanded our installed based to include more than 5,000 flow cytometry systems worldwide, adding to our impressive footprint and creating the potential for additional meaningful growth."

The buyout is expected to contribute \$40-\$50 million in revenue to Luminex in 2019.